The text discusses the challenge of determining the differences between prior art and claims in patents related to drug combinations. It highlights the Supreme Court's caution in granting a patent based on prior art elements and explores situations where a patent may be considered obvious.
![]()
https://www.jdsupra.com/legalnews/obviousness-in-drug-combinations-6311291/
https://www.jdsupra.com/legalnews/obviousness-in-drug-combinations-6311291/